Skip to content

Supported exercise training for men on androgen deprivation therapy (WP3)

Supported exercise TrAining for Men wIth prostate caNcer on Androgen deprivation therapy - the STAMINA programme: work package 3

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN15691664
Enrollment
64
Registered
2019-04-04
Start date
2019-05-19
Completion date
Unknown
Last updated
2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer Cancer Prostate Cancer

Interventions

Patient intervention: Up to 32 men from 4 sites on long-term ADT will be referred for supervised exercise training for 12 weeks. The process can be broken down into distinct steps. Ste

Sponsors

Sheffield Teaching Hospitals NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria for HCPs: 1.1 Involved in diagnosis and or treatment and or follow-up of men with prostate cancer on ADT 1.2 Able and willing to receive draft intervention training for HCPs as developed in STAMINA Work Package 2 (HRA approved: IRAS number 254343) 1.3 Based at a site with sufficient number of men started on long-term ADT to achieve recruitment target within timelines. 2. Inclusion criteria for men on ADT: 2.1 Prostate cancer within 12 months of starting ADT (at time of screening). 2.2 Receiving continuous ADT for a planned minimum of 12 months treatment 2.3 Willing and able to provide informed consent 2.4 Not due to receive chemotherapy within 3 months or those having completed chemotherapy

Exclusion criteria

Exclusion criteria: 1. Exclusion criteria for HCPs: 1.1 Inability to read or speak English to an appropriate level 2. Exclusion criteria for participants: 2.1 Men with unstable angina 2.2 Uncontrolled hypertension and/ or diabetes mellitus 2.3 Recent myocardial infarction (within past 6 months) 2.4 Unable to provide informed consent (lack capacity) 2.5 Painful or unstable bony metastases 2.6 Fixed output pacemakers 2.7 Due to commence chemotherapy within 3 months

Design outcomes

Primary

MeasureTime frame
Primary outcome in this context is not applicable. Data generated will be purely descriptive and are required to inform the refinement and optimisation of our complex intervention which will be evaluated during our subsequent planned multi-centre RCT.

Countries

England, United Kingdom

Contacts

Public ContactRebecca Turner
Rebecca.turner@sth.nhs.uk0114 2252410

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026